WZWen Zhong

Wen Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects

Research Interests


Wen Zhong has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Aimin Du

    CAS Engineering Laboratory for Deep Resources Equipment and Technology Institute of Geology and Geophysics Chinese Academy of Sciences Beijing China

    1 shared publication
  • Jiaoe Zeng

    Department of Endocrine, Jingzhou Central Hospital and The Second Clinical Medical College, Yangtze University, Jingzhou, 434020, Hubei, China

    1 shared publication
  • Junli Xue

    Department of Oncology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, PR China

    1 shared publication
  • Yancheng Xu

    Department of Endocrinology, Zhongnan Hospital of Wuhan University, 169 East Lake Road, Wuchang District, Wuhan, 430071, Hubei, China

    1 shared publication

Latest Publications

  • Open Access

    Knockdown of lncRNA PVT1 alleviates high glucose-induced proliferation and fibrosis in human mesangial cells by miR-23b-3p/WT1 axis

    by Wen Zhong, Jiaoe Zeng, Junli Xue, Aimin Du, Yancheng Xu

    Background: Diabetic nephropathy (DN) is a severe complication of diabetes with type 1 and 2. Long non-coding RNAs (lncRNAs) are being found to be involved in the DN pathogenesis. In this study, we aimed to further explore the effect and underlying mechanism of plasmacytoma variant translocation 1 (PVT1) in DN pathogenesis. Methods: The expression levels of PVT1, miR-23b-3p, and Wilms tumor protein 1 (WT1) mRNA were assessed by quantitative real-time polymerase chain reaction (qRT-PCR). Western blot analysis was performed to determine protein expression. Cell proliferation was detected using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr-azolium (MTS) assay. The targeted correlation between miR-23b-3p and PVT1 or WT1 was verified by dual-luciferase reporter assay. Results: PVT1 and WT1 were highly expressed in the serum of DN patients and high glucose (HG)-induced mesangial cells (MCs). The knockdown of PVT1 or WT1 ameliorated HG-induced proliferation and fibrosis in MCs. Mechanistically, PVT1 modulated WT1 expression through acting as a molecular sponge of miR-23b-3p. The miR-23b-3p/WT1 axis mediated the protective effect of PVT1 knockdown on HG-induced proliferation and fibrosis in MCs. The NF-κB pathway was involved in the regulatory network of the PVT1/miR-23b-3p/WT1 axis in HG-induced MCs. Conclusion: Our study suggested that PVT1 knockdown ameliorated HG-induced proliferation and fibrosis in MCs at least partially by regulating the miR-23b-3p/WT1/NF-κB pathway. Targeting PVT1 might be a potential therapeutic strategy for DN treatment.